TY - JOUR
T1 - Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis
T2 - A two-year randomized, double blind, double placebo study
AU - Ebeling, Peter R.
AU - Wark, John D.
AU - Yeung, Stella
AU - Poon, Cathy
AU - Salehi, Nouria
AU - Nicholson, Geoffrey C.
AU - Kotowicz, Mark A.
PY - 2001/1/1
Y1 - 2001/1/1
N2 - Osteoporosis in men is an emerging public health problem. As calcitriol reduces the rate of vertebral fractures in osteoporotic postmenopausal women, we conducted a prospective study of this treatment in men with primary osteoporosis. Our study was a 2-yr, randomized, double masked, double placebo-controlled trial of calcitriol (0.25 μg twice daily) or calcium (500 mg twice daily) in 41 men with primary osteoporosis and at least 1 baseline fragility fracture. Thirty-three men (85%) completed the study. There were no differences in baseline characteristics. Spinal and femoral neck bone mineral densities at 2 yr were unchanged in both groups. Serum osteocalcin decreased in both groups by 30% (P < 0.05), whereas urine N-telopeptide cross-links decreased only in the calcium group by 30% (P < 0.05). After 2 yr, fractional calcium absorption increased by 34% (P < 0.01) in the calcitriol group. Nineteen incident fragility fractures occurred (14 vertebral and 5 nonvertebral) in 7 men. Over 2 yr, the number of men with vertebral fractures (6 vs. 1; P = 0.097) was similar in both groups. In conclusion, the efficacy of calcitriol remains unproven as a single agent for the treatment of osteoporosis in men.
AB - Osteoporosis in men is an emerging public health problem. As calcitriol reduces the rate of vertebral fractures in osteoporotic postmenopausal women, we conducted a prospective study of this treatment in men with primary osteoporosis. Our study was a 2-yr, randomized, double masked, double placebo-controlled trial of calcitriol (0.25 μg twice daily) or calcium (500 mg twice daily) in 41 men with primary osteoporosis and at least 1 baseline fragility fracture. Thirty-three men (85%) completed the study. There were no differences in baseline characteristics. Spinal and femoral neck bone mineral densities at 2 yr were unchanged in both groups. Serum osteocalcin decreased in both groups by 30% (P < 0.05), whereas urine N-telopeptide cross-links decreased only in the calcium group by 30% (P < 0.05). After 2 yr, fractional calcium absorption increased by 34% (P < 0.01) in the calcitriol group. Nineteen incident fragility fractures occurred (14 vertebral and 5 nonvertebral) in 7 men. Over 2 yr, the number of men with vertebral fractures (6 vs. 1; P = 0.097) was similar in both groups. In conclusion, the efficacy of calcitriol remains unproven as a single agent for the treatment of osteoporosis in men.
UR - http://www.scopus.com/inward/record.url?scp=0034855084&partnerID=8YFLogxK
U2 - 10.1210/jcem.86.9.7847
DO - 10.1210/jcem.86.9.7847
M3 - Article
C2 - 11549632
AN - SCOPUS:0034855084
VL - 86
SP - 4098
EP - 4103
JO - The Journal of Clinical Endocrinology and Metabolism
JF - The Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 9
ER -